**Poly-substance use, treatment completion, and contact with the justice system: a multistate analysis of treatments for substance use disorders between 2010-2019 in Chile**

# Background (456)

Evidence shows that substance use disorders (SUD) are related to criminality, such as reincarceration1, arrests2, and violence3. People with SUD also tend to use more than one substance (PSU)4 during active use in their lifetime5.

6Research conducted in North America, Europe, and Australia has shown that using multiple substances leads to a higher mortality rate6, is related to post-traumatic stress disorder7, increases the risk of relapse compared to single substance use, and is more prevalent among young males with low education6,8,9. Additionally, the PSU prevalence tends to be higher among people with SUD in contact with the criminal justice system (CCJS)10,11.

Research on PSU in Latin America is considerably limited12. Furthermore, and like many studies in the global north, high-risk populations have often been overlooked13. An analysis of data from independent studies conducted in six Latin American countries found that 21% of participants had PSU, and males, people aged 18-34 years, from Chile, Uruguay, and Argentina were more likely to report PSU13. Studies conducted in hard-to-reach populations in Chile have associated PSU with school drop-out, unemployment, sexual risk, and antisocial behaviors14–16.

One major issue highlighted in the literature is the role of treatment in patients’ substance use trajectories. Completing treatment is associated with better outcomes, but patient characteristics may influence completion rates, including their pattern of substance use17–19. A US veterans’ sample study showed that completing SUD intensive-outpatient treatment lowered the likelihood of CCJS20, while another study found that prior SUD treatment is protective against CCJS21. Analyses must consider differences in treatment goals, patient characteristics, resource availability, and SUD severity profiles, which may affect the relationship between PSU, treatment completion, and CCJS22–24.

Although the relationship between SUD and CCJS is well documented in the global north, little is known about the effect of treatment outcomes among people with PSU in other contexts. This study aims to estimate the mediating effects of completing SUD treatment on the link between PSU and CCJS among adult patients admitted to SUD treatment programs in Chile during 2010-2019. Understanding this relationship could inform effective prevention and intervention strategies for PSU and provide insight into the effectiveness of SUD treatment in reducing the risk of CCJS among individuals with baseline PSU in Chile. This study contributes to a growing literature on the importance of addressing longitudinal dynamics in SUD patients.

# Research questions, aims, and hypothesis

* **Research question:** What are the mediating effects of completing SUD treatment on the relationship between baseline PSU and CCJS in Chile in the short (six months), middle (1 year), and long term (3 years)?
* **Aims:** Estimate the mediating effects of completing SUD treatment on the relationship between PSU at admission and CCJS among adult patients admitted to SUD treatment programs in Chile during 2010-2019. Specific: (1) To describe PSU, treatment completion, CCJS patient and confounders, (2) to compare the risk of CCJS system between people with poly and single-substance use, and (3) to estimate the proportion of the effect of PSU and treatment outcome on the CCJS.
* **Hypothesis:** Baseline PSU is related to lower treatment completion rates (1), baseline PSU is related to a greater risk of CCJS (2), patients with PSU will have a differential risk of CCJS associated with treatment completion, and treatment completion will explain part of the relationship between PSU and CCJS (3).

# Methodology

This research design is a retrospective cohort based on the administrative data's record linkage. The study will use data from Chilean SUTs programs and Prosecutor’s Office through a deterministic linkage process. The study is exempted from ethics review as it uses de-identified data. The exposure variable will be the baseline PSU (using more than one main substance among alcohol and illicit drugs at admission to SUD treatment, whether sequential or concurrent)25,26, the mediator variable will be SUD treatment outcome (complete vs. dropout or spelled by misconduct), and the outcome will be CCJS (offense that led to a condemnatory sentence). The study will control for various confounding variables related to substance use, demographics, and social factors through weights generated through the inverse probability of PSU27. We will use the illness-death multistate model to simultaneously estimate transitions between admission and treatment outcome, treatment outcome and CCJS, and admission and CCJS (without completing treatment). We will then calculate the Aalen-Johansen estimator for transition probabilities at 6 months, 1 and 3 years27. Secondary analyses will focus on mediation, estimating the effects of PSU given treatment outcome at 6 months, 1 and 3 years using a standard time-to-first-event approach. Proportions mediated will be estimated using the bootstrap method. We also plan to run separate analyses in patients admitted to outpatient vs inpatient treatment. Preliminary markdowns are available at bit.ly/3w9wygJ.

# Project milestones

* **Progress report:** It will include: a theoretical framework and descriptive analyses exploring the connections between PSU, SUT outcome, and CCJS.
* **Paper:** Sent to a Substance Abuse, Criminology or Public Health international journal before the months 12 of the study.
* **Presentation in Scientific meetings:** Our goal is to present this study at least at one international conference such as the Society for Epidemiologic Research or similar, and in possible scientific community activities organized either by Universidad de Chile or other national institutions.

# Research team

Our research team has experience in public health and criminology and has skills in the use of large datasets in substance use epidemiology, program and policy evaluation, and treatment research (See Table 1). Previously, part of the team collaborated on SUT policy analysis publications.

**Table 1. Research team.**

|  |  |  |  |
| --- | --- | --- | --- |
| Name | Role | Expertise | Time spent |
| Andrés González | P.I. | Ph.D. student (School of Public Health, Universidad de Chile). He has worked as technical staff in research related to occupational health and SUD treatments. He has been working on the Treatment patients dataset since 2019, collaborating with Dr. Castillo-Carniglia in several papers | *6 hours per week* |
| José Ruiz-Tagle | Co-I | Ph.D. student (Public Policy, Universidad Mayor). He has worked in research projects related to substance use treatments. He also has been working on the dataset on Treatment patients since 2019 along with Dr. Castillo-Carniglia. He collaborated in the analysis of several papers linked to SUD. | *3 hours per week* |
| Mariel Mateo | Co-I | Ph.D. student (School of Criminology and Criminal Justice, Griffith University, Australia). She coordinated the first Outcome Study of Substance Use Treatment in Chile and led the Drug research area in the Justice and Society Studies Centre (Pontificia Universidad Católica) between 2015 and 2019. | *2 hours per week* |
| *Álvaro Castillo-Carniglia* | Sup | Ph.D., Associate professor, and Director of the Ph.D. Programme in Public Policy, Universidad Mayor. He has a background in epidemiology and his main research areas are the measurement of SUDs in the population. He has co-directed several theses in public health related to treatment dropouts and readmissions. | *2 hours fortnight* |
| *Note: P.I.: Principal Investigator; Co-I: Co-Investigator; Sup.: Supervisor.* | | | |

# Timeline

Based on the work carried out in the 2022 intramural fund, we will delve into the transformation and processing of data following a longitudinal perspective of nested events by subjects. Additionally, a significant amount of time will be devoted to discussing and implementing knowledge of causal inference involved in the analysis. The process is summarized in Figure 1.

**Figure 1. Gantt chart of activities involved in research progress.**

Imagen que contiene Tabla

Descripción generada automáticamente

# Budget

Funds will be used to cover expenses for attending international conferences and for a virtual computer (e.g., an annual subscription to DataCamp Teams). The cost of attending international conferences is between 2,000-4,000 USD28, thus the funds should cover a significant portion of these expenses. Also, it can be used for workshops, manuscript editing (if needed), and as an incentive for the researchers.

# References

1. Thomas EG, Spittal MJ, Taxman FS, Puljević C, Heffernan EB, Kinner SA. Association between contact with mental health and substance use services and reincarceration after release from prison. *PLoS One*. 2022;17(9):e0272870. doi:10.1371/journal.pone.0272870

2. Sugie NF, Turney K. Beyond Incarceration: Criminal Justice Contact and Mental Health. *Am Sociol Rev*. 2017;82(4):719-743. doi:10.1177/0003122417713188

3. Duke AA, Smith KMZ, Oberleitner LMS, Westphal A, McKee SA. Alcohol, drugs, and violence: A meta-meta-analysis. *Psychol Violence*. 2018;8(2):238-249. doi:10.1037/vio0000106

4. Liu Y, Williamson V, Setlow B, Cottler LB, Knackstedt LA. The importance of considering polysubstance use: lessons from cocaine research. *Drug Alcohol Depend*. 2018;192:16-28. doi:10.1016/j.drugalcdep.2018.07.025

5. Connor JP, Gullo MJ, White A, Kelly AB. Polysubstance use. *Curr Opin Psychiatry*. 2014;27(4):269-275. doi:10.1097/YCO.0000000000000069

6. Gjersing L, Bretteville-Jensen AL. Patterns of substance use and mortality risk in a cohort of ‘hard-to-reach’ polysubstance users. *Addiction*. 2018;113(4):729-739. doi:10.1111/add.14053

7. Hassan AN, Le Foll B. Polydrug use disorders in individuals with opioid use disorder. *Drug Alcohol Depend*. 2019;198:28-33. doi:10.1016/j.drugalcdep.2019.01.031

8. Wang L, Min JE, Krebs E, et al. Polydrug use and its association with drug treatment outcomes among primary heroin, methamphetamine, and cocaine users. *International Journal of Drug Policy*. 2017;49:32-40. doi:10.1016/j.drugpo.2017.07.009

9. Quek LH, Chan GCK, White A, et al. Concurrent and Simultaneous Polydrug Use: Latent Class Analysis of an Australian Nationally Representative Sample of Young Adults. *Front Public Health*. 2013;1. doi:10.3389/fpubh.2013.00061

10. Ford JA, Ortiz K, Schepis TS, McCabe SE. Types of criminal legal system exposure and polysubstance use: Prevalence and correlates among U.S. adults in the National Survey on Drug Use and Health, 2015–2019. *Drug Alcohol Depend*. 2022;237:109511. doi:10.1016/j.drugalcdep.2022.109511

11. Skjaervø I, Skurtveit S, Clausen T, Bukten A. Substance use pattern, self-control and social network are associated with crime in a substance-using population. *Drug Alcohol Rev*. 2017;36(2):245-252. doi:10.1111/dar.12406

12. Lalwani K, Whitehorne-Smith P, Walcott G, McLeary JG, Mitchell G, Abel W. Prevalence and sociodemographic factors associated with polysubstance use: analysis of a population-based survey in Jamaica. *BMC Psychiatry*. 2022;22(1):513. doi:10.1186/s12888-022-04160-2

13. Reyes JC, Perez CM, Colon HM, Dowell MH, Cumsille F. Prevalence and Patterns of Polydrug Use in Latin America: Analysis of Population-based Surveys in Six Countries. *Rev Eur Stud*. 2013;5(1). doi:10.5539/res.v5n1p10

14. Santis B R, Hidalgo C CG, Hayden C V, et al. Consumo de sustancias y conductas de riesgo en consumidores de pasta base de cacaína no consultantes a servicios de rehabilitación. *Rev Med Chil*. 2007;135(1). doi:10.4067/S0034-98872007000100007

15. Olivari CF, Gaete J, Rodriguez N, et al. Polydrug Use and Co-occurring Substance Use Disorders in a Respondent Driven Sampling of Cocaine Base Paste Users in Santiago, Chile. *J Psychoactive Drugs*. 2022;54(4):348-357. doi:10.1080/02791072.2021.1976886

16. Vilugrón F, Molina G. T, Gras-Pérez ME, Font-Mayolas S. Precocidad de inicio del consumo de sustancias psicoactivas y su relación con otros comportamientos de riesgo para la salud en adolescentes chilenos. *Rev Med Chil*. 2022;150(5):584-596. doi:10.4067/s0034-98872022000500584

17. White W. Recovery/remission from substance use disorders: an analysis of reported outcomes in 415 scientific reports, 1868–2011. 2012. Philadelphia Department of Behavioral Health and Intellectual disAbility Services and the Great Lakes Addiction Technology Transfer Center: Chicago, Illinois & Philadelphia, PA. Accessed March 13, 2023. https://www.naadac.org/assets/2416/whitewl2012\_recoveryremission\_from\_substance\_abuse\_disorders.pdf

18. Andersson HW, Wenaas M, Nordfjærn T. Relapse after inpatient substance use treatment: A prospective cohort study among users of illicit substances. *Addictive Behaviors*. 2019;90:222-228. doi:10.1016/j.addbeh.2018.11.008

19. Rezai-Zadeh KP, Engstrom RN, Sharma A, et al. Generational trends and patterns in readmission within a statewide cohort of clients receiving heroin use disorder treatment in Maryland, 2007–2013. *J Subst Abuse Treat*. 2019;96:82-91. doi:https://doi.org/10.1016/j.jsat.2018.10.010

20. Timko C, Nash A, Owens MD, Taylor E, Finlay AK. Systematic Review of Criminal and Legal Involvement After Substance Use and Mental Health Treatment Among Veterans: Building Toward Needed Research. *Subst Abuse*. 2020;14:117822181990128. doi:10.1177/1178221819901281

21. Nkemjika S, Olatunji E, Olwit C, et al. Comorbid Substance Use and Mental Health Disorders: Prior Treatment/Admission as a Predictor of Criminal Arrest Among American Youths. *Cureus*. Published online January 24, 2022. doi:10.7759/cureus.21551

22. Reif S, Stewart MT, Torres ME, Davis MT, Dana BM, Ritter GA. Effectiveness of value-based purchasing for substance use treatment engagement and retention. *J Subst Abuse Treat*. 2021;122:108217. doi:10.1016/j.jsat.2020.108217

23. Tiet QQ, Ilgen MA, Byrnes HF, Harris AHS, Finney JW. Treatment setting and baseline substance use severity interact to predict patients’ outcomes. *Addiction*. 2007;102(3):432-440. doi:10.1111/j.1360-0443.2006.01717.x

24. Fiestas F, Ponce J. Eficacia de las comunidades terapéuticas en el tratamiento de problemas por uso de sustancias psicoactivas: una revisión sistemática. *Rev Peru Med Exp Salud Publica*. 2012;29(1):12-20. https://www.redalyc.org/articulo.oa?id=36323255003

25. Font-Mayolas S, Calvo F. Polydrug Definition and Assessment: The State of the Art. *Int J Environ Res Public Health*. 2022;19(20):13542. doi:10.3390/ijerph192013542

26. Crummy EA, O’Neal TJ, Baskin BM, Ferguson SM. One Is Not Enough: Understanding and Modeling Polysubstance Use. *Front Neurosci*. 2020;14. doi:10.3389/fnins.2020.00569

27. Crowther MJ, Lambert P. MULTISTATE: Stata module to perform multi-state survival analysis. Published online January 18, 2023. https://EconPapers.repec.org/RePEc:boc:bocode:s458207

28. Sarabipour S, Khan A, Seah S, et al. Evaluating features of scientific conferences: A call for improvements. Published online 2020. doi:10.1101/2020.04.02.022079